The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2022 | Pathogenesis and transformation in CLL: session highlights
In this video, Kostas Stamatopoulos, MD, PhD, Center for Research and Technology Hellas, Thessaloniki, Greece, highlights some of the main points from a session held at ESH CLL 2022, which focused on pathogenesis and transformation in chronic lymphocytic leukemia (CLL). Dr Stamatopoulos first discusses the pathogenesis of disease, where Dr Alberto Orfao gave a presentation on monoclonal B-cell lymphocytosis (MBL) and progression to CLL. Following this, Dr Stamatopoulos highlights some other talks in this session, including high-risk CLL, Richter’s transformation, and the need to better understand these in order to prevent occurrence and improve management. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
